Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Apotex Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (1354)
Cancellation or suspension (47)
Prescription medicine registration (18)
ARTG (8)
Australian Public Assessment Report (AusPAR) (1)
Listed medicine compliance report (1)
Prescription medicine decision summary (1)
Section 14, TGO91 consent (1)

Date

2024 (4)
2023 (16)
2022 (159)
2021 (104)
2020 (216)
2019 (124)
2018 (380)
2017 (307)
2016 (37)
2015 (52)
2014 (32)

Results for "[search-keyword]"

Search

Sponsor content

1431 result(s) found, displaying 681 to 690

APOTEX-OLANZAPINE olanzapine 20 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 July 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
APOTEX-OLANZAPINE olanzapine 2.5 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 July 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
DASATINIB APOTEX, APO-DASATINIB (Apotex Pty Ltd)

25 July 2018

Prescription medicine registration

Active ingredients: Dasatinib.
APO-Entecavir entecavir (as monohydrate) 0.5mg tablet blister pack Section 30(1)(c) of the Act

11 July 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
APO-Entecavir entecavir (as monohydrate) 1mg tablet blister pack Section 30(1)(c) of the Act

11 July 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
PHARMACY CARE AMOROLFINE ANTI FUNGAL NAIL TREATMENT amorolfine 5% w/v (as hydrochloride) nail lacquer application bottle Cancelled under Section 30(1)(c) of the Act

29 June 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
GENRX CANDESARTAN candesartan cilexetil 4 mg tablet blister Cancelled under Section 30(1)(c) of the Act

25 June 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
GENRX CANDESARTAN candesartan cilexetil 8 mg tablet blister Cancelled under Section 30(1)(c) of the Act

25 June 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
GENRX CANDESARTAN candesartan cilexetil 32mg tablets blister Cancelled under Section 30(1)(c) of the Act

25 June 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd
GENRX CANDESARTAN candesartan cilexetil 16 mg tablets blister Cancelled under Section 30(1)(c) of the Act

25 June 2018

Cancellation by sponsor

Requested by Apotex Pty Ltd

Pages

First page
Previous page
…
Page 65
Page 66
Page 67
Page 68
Current page 69
Page 70
Page 71
Page 72
Page 73
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.